Join the BioNap Email List:

BioNap Client List

BioNap is party to a services agreement with some companies covered on this blog, pursuant to which BioNap is paid in exchange for the provision of research reports, investor relations services, and general consulting services. 

Past and/or current BioNap, Inc. clients include:

- RedHill Biopharma Ltd. (RDHL) at a rate of $2,500 to 5,000 per month to BioNap for the provision of research reports and investor relations services.

- CanFite Biopharma (CANF) at a rate of $5,000 per month to BioNap for the provision of research reports, investor relations services, and assistance on business development activities.

- Immune Pharmaceuticals (IMNP) at a rate of $5,000 per month to BioNap for the provision of research reports and investor relations services.

- IRTH Communications, an investor relations and strategic consulting company, at a rate of $4,000 per month to BioNap for the provision of research reports on Oasmia Pharmaceuticals (OASM), Actinium Pharmaceuticals (ATNM), 22nd Century Group Inc. (XXII), MabVax Therapeutics (MBVX), Relmada Therapeutics (RLMD), and BioSig Technologies Inc. (BSGM).

- Revive Therapeutics (RVV.V) at a rate of $3,333 per month to BioNap for the provision of research reports and investor relations services.

- HedgePath Pharma, at a rate of $4,000 per month to BioNap for the provision of research reports, investor relations services, and assistance on business development activities.

- Matinas Biopharma, at a rate of $4,000 per month to BioNap for the provision of research reports, investor relations services, and assistance on business development activities.

- BriaCell Therapeutics (BCT.V) at a rate of $2,000 per month to BioNap and has granted Jason Napodano, founder and chief officer of BioNap, 500,000 stock options for the provision of research reports and investor relations services.

- InVivo Therapeutics (NVIV) at a rate of $2,500 for conducting a CEO Interview.

- Exactus Inc (EXDI) has granted Jason Napodano, founder and chief officer of BioNap, 150,000 shares of restricted Series-B1 stock for the provision of research reports and investor relations services.

- BrianStorm Cell Therapeutics (BCLI) at a rate of $4,000 per month to BioNap for the provision of research reports and investor relations services.


- Vaxil Bio Ltd (VXL.V) at a rate of $2,000 per month to BioNap and has granted Jason Napodano, founder and chief officer of BioNap, 75,000 stock options for the provision of research reports and investor relations services.

- VistaGen Therapeutics (VTGN) at a rate of $4,000 per month to BioNap for the provision of research reports and investor relations services.

- Oryzon Genomics (ORY) at a rate of $1,500 to $5,000 per report to BioNap for the provision of research reports and investor relations services.


- Blackrock Media Group Inc. at a rate of $4,000 per month to BioNap for the provision of research reports on Vitality Biopharma Inc. (VBIO).

- Valeritas Holdings Inc. (VLRX) at a rate of $3,333 per month to BioNap for the provision of research reports and investor relations services.

- Pieris Pharmaceuticals (PIRS) at a rate of $5,000 to BioNap for the provision of a research reports and investor relations services.

- King Fish Media, a digital marketing firm, at a rate of $2,500 to $3,500 per report to BioNap for the provision of research reports and investor relations services to CoLucid Pharmaceuticals, Inc. (CLCD).


BioNap has also provided exclusive market research, investor relations consulting services, and due diligence on business development activities to several companies, both public and private, none of which has been shared publicly. BioNap expects to continue to provide strategic consulting services to companies, both public and private, in the future that may or may not result in confidential material to be used by the company, not shared on the blog. BioNap reserves the right to hold these projects, including fees earned for providing general consulting services and project work, as confidential material.

No comments:

Post a Comment